Quantcast

Latest C-peptide Stories

2008-10-30 09:00:11

Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes. BHT-3021 is an antigen-specific immunotherapeutic DNA vaccine designed to reverse the underlying autoimmune...

2008-09-23 09:00:15

CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. announced it presented results from a Phase 1 clinical study with PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of the chronic treatment of heart failure, at the 12th Annual Scientific Meeting of the Heart Failure Association of America at the Metro Toronto Convention Centre, Toronto, Ontario, Canada on September 22, 2008. The Phase 1 trial was a...

2008-09-03 09:00:07

TEMPE, Ariz., Sept. 3, 2008 (GLOBE NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the publication of positive results from a pre-clinical study of Chrysalin(r) (rusalatide acetate or TP508) in a model of chronic myocardial ischemia. The study demonstrates that Chrysalin significantly increases vascular perfusion and myocardial function in porcine hearts with induced chronic myocardial ischemia. Cardiovascular disease is the leading cause of death in the United States, according...

2008-08-07 12:01:26

Tolerx has started a pivotal Phase III clinical trial that is evaluating otelixizumab in autoimmune new onset type 1 diabetes. Defend is a randomized, placebo controlled Phase III trial designed to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. Defend is being conducted at multiple centers in North America and Europe. The trial will evaluate whether a single course of otelixizumab, administered not more than 90 days after the...

2008-08-06 12:00:58

JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)(http://www.oramed.com/), a developer of oral delivery systems, announced today successful results from the clinical trial of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a good safety profile and was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes. The study was conducted at Hadassah University Medical Center in...

2008-08-06 09:01:04

Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced that it has been issued U.S. Patent number 7,407,940 by the United States Patent and Trademark Office, which includes the company's lead pre-clinical lipohexapeptide candidates. The patent covers a family of hexapeptide antimicrobial agents, including HB1345, for use as broad spectrum topical anti-infectives. HB1345 will be developed initially for dermatological indications such acne, rosacea and...

2008-07-30 12:01:17

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. , today announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure. The primary objective of the study is to assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters of intravenous infusions of CD-NP in patients with heart failure. Key...

2008-07-15 12:01:01

-- GelVac(tm) Nasal Powder Platform Delivers Peptide Arginine-Vasopressin (AVP) Into Systemic Circulation -- Peptide Widely Used to Control Urine Output in Patients With Diabetes Insipidus -- Additional Commercial Opportunities Could Include a Treatment for Heart Failure -- Formulation Stable at Room Temperature For More Than 18 Months IRVING, Texas, July 15, 2008 (PRIME NEWSWIRE) -- DelSite, Inc. (OTCBB:CARN) announced that its GelVac(tm) intranasal powder...

2008-07-11 09:01:07

SAN FRANCISCO, July 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. , today announced that it has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure. The primary objective of the Phase IIa study is to assess hemodynamic effects of intravenous infusions of...

2008-06-25 09:02:22

Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved $2 million in milestone payments from the Juvenile Diabetes Research Foundation (JDRF) for progress made on a Phase II clinical trial evaluating Prochymal, a mesenchymal stem cell (MSC) therapy, for patients recently diagnosed with type 1 diabetes. The payments were triggered when Osiris accomplished certain clinical and regulatory milestones including initiating patient treatments. "Due to the long-term effects of...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'